Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what recent assessment has been made of the effect of Gadolinium on health outcomes.
The Medicines and Healthcare products Regulatory Agency participated in a recent European-level review of gadolinium retention in the brain and other tissues following exposure to gadolinium-containing contrast agent used to enhance magnetic resonance imaging scans. The review, which completed on 24 November 2017, included a comprehensive assessment of available scientific evidence on the implication of retention of low levels of gadolinium in the brain and other tissues. The assessment found no evidence that gadolinium deposition in the brain has caused adverse neurological effects in patients, but data on long-term effects of gadolinium deposition are very limited.
The outcome of the review can be found at: